FDA allows marketing of non-invasive device to help evaluate heart blood flow

Share this content:
FDA allows marketing of non-invasive device to help evaluate heart blood flow
FDA allows marketing of non-invasive device to help evaluate heart blood flow
The U.S. Food and Drug Administration has allowed marketing of the HeartFlow FFR-CT software, which permits health care professionals to non-invasively evaluate blood flow in the coronary arteries of patients showing signs and symptoms of coronary artery disease. The HeartFlow FFR-CT software can non-invasively provide an estimate of FFR using data from a computed tomography (CT) scan of the patient's heart.
READ FULL ARTICLE From Medical News Today
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »